- level: Info
  location: {}
  message: Importing FHIR PRISM3
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: 'Extracted identifier of type ''Sponsor Protocol Identifier'': ''I8R-JE-IGBJ'''
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: Sponsor org found
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Debug
  location:
    class_name: usdm4_fhir.m11.import_.import_prism3.ImportPRISM3
    method_name: _to_address
  message: 'Address: is valid, {''country'': ''Japan'', ''text'': ''Japan''}'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: 'Extracted identifier of type ''Amendment Identifier'': ''I8R-JE-IGBJ(a)'''
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: Co sponsor org not found
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Warning
  location: {}
  message: Unable to extract co-sponsor details from associated parties
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: Local sponsor org not found
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Warning
  location: {}
  message: Unable to extract local sponsor details from associated parties
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: Device manufacturer sponsor org not found
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Warning
  location: {}
  message: Unable to extract device manufacturer details from associated parties
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: 'Scope extracted {''global'': True, ''countries'': [], ''regions'': [],
    ''sites'': [], ''unknown'': []}'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: 'Impact extracted {''safety_and_rights'': {''safety'': {''substantial'':
    True, ''reason'': ''Specifically implemented to decrease safety risks.''}, ''rights'':
    {''substantial'': True, ''reason'': ''Specifically implemented to decrease safety
    risks.''}}, ''reliability_and_robustness'': {''reliability'': {''substantial'':
    False, ''reason'': ''''}, ''robustness'': {''substantial'': False, ''reason'':
    ''''}}}'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: "Amendment extract {'identifier': 'I8R-JE-IGBJ(a)', 'scope': {'global':\
    \ True, 'countries': [], 'regions': [], 'sites': [], 'unknown': []}, 'enrollment':\
    \ {'value': 0, 'unit': ''}, 'reasons': {'primary': 'Primary: Other', 'secondary':\
    \ 'Secondary: Other'}, 'summary': 'Protocol I8R-JE-IGBJ A Phase 3 Study of Nasal\
    \ Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced\
    \ Hypoglycemia in Japanese Patients with Diabetes Mellitus has been amended. The\
    \ new protocol is indicated by Amendment (a) and will be used to conduct the study\
    \ in place of any preceding version of the protocol. The overall changes and rationale\
    \ for the changes made to this protocol are as follows: \\nAn exclusion criterion\
    \ for patients with retinopathy or maculopathy was added due to the potential\
    \ risk of fundal hemorrhage induced by hypoglycemia. \\nThe GlucaGen reconstitution\
    \ volume was changed from 1.0 mL to 1.1 mL in accordance with instructions in\
    \ the Summary of Product Characteristics (2015). Protocol I8R-JE-IGBJ A Phase\
    \ 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for\
    \ Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes\
    \ Mellitus has been amended. The new protocol is indicated by Amendment (a) and\
    \ will be used to conduct the study in place of any preceding version of the protocol.\
    \ The overall changes and rationale for the changes made to this protocol are\
    \ as follows: \u2022 An exclusion criterion for patients with retinopathy or maculopathy\
    \ was added due to the potential risk of fundal hemorrhage induced by hypoglycemia.\
    \ \u2022 The GlucaGen reconstitution volume was changed from 1.0 mL to 1.1 mL\
    \ in accordance with instructions in the Summary of Product Characteristics (2015).\
    \ Protocol I8R-JE-IGBJ A Phase 3 Study of Nasal Glucagon (LY900018) Compared to\
    \ Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese\
    \ Patients with Diabetes Mellitus has been amended. The new protocol is indicated\
    \ by Amendment (a) and will be used to conduct the study in place of any preceding\
    \ version of the protocol. The overall changes and rationale for the changes made\
    \ to this protocol are as follows: \u2022 An exclusion criterion for patients\
    \ with retinopathy or maculopathy was added due to the potential risk of fundal\
    \ hemorrhage induced by hypoglycemia. \u2022 The GlucaGen reconstitution volume\
    \ was changed from 1.0 mL to 1.1 mL in accordance with instructions in the Summary\
    \ of Product Characteristics (2015).', 'impact': {'safety_and_rights': {'safety':\
    \ {'substantial': True, 'reason': 'Specifically implemented to decrease safety\
    \ risks.'}, 'rights': {'substantial': True, 'reason': 'Specifically implemented\
    \ to decrease safety risks.'}}, 'reliability_and_robustness': {'reliability':\
    \ {'substantial': False, 'reason': ''}, 'robustness': {'substantial': False, 'reason':\
    \ ''}}}, 'changes': [{'description': 'An exclusion criterion for patients with\
    \ retinopathy or maculopathy was added due to the potential risk of fundal hemorrhage\
    \ induced by hypoglycemia.', 'rationale': 'Mitigate risk of fundal hemorrhage\
    \ induced by hypoglycemia.', 'section': 'Section 6'}, {'description': 'The GlucaGen\
    \ reconstitution volume was changed from 1.0 mL to 1.1 mL in accordance with instructions\
    \ in the Summary of Product Characteristics (2015).', 'rationale': 'Ensure alignment\
    \ with Summary of Product Characteristics (2015)', 'section': 'Section 9'}]}"
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Warning
  location: {}
  message: Failed to extract identifier of type 'C218685'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Warning
  location: {}
  message: Failed to extract identifier of type 'C218684'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: 'Extracted identifier of type ''NCT Number'': ''NCT03421379'''
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Debug
  location:
    class_name: usdm4.assembler.identification_assembler.IdentificationAssembler
    method_name: _create_address
  message: 'Creating address, source data: {''country'': ''Japan'', ''text'': ''Japan''}'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.assembler.identification_assembler.IdentificationAssembler
    method_name: _create_address
  message: Address set to Japan
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Debug
  location:
    class_name: usdm4.assembler.identification_assembler.IdentificationAssembler
    method_name: _create_address
  message: 'Creating address, source data: {''lines'': [''National Library of Medicine'',
    ''8600 Rockville Pike''], ''city'': ''Bethesda'', ''district'': '''', ''state'':
    ''MD'', ''postalCode'': ''20894'', ''country'': ''USA''}'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.assembler.identification_assembler.IdentificationAssembler
    method_name: _create_address
  message: Address set to National Library of Medicine, 8600 Rockville Pike, Bethesda,
    MD, 20894, United States of America
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.encoder.encoder.Encoder
    method_name: document_status
  message: Document status 'FINAL' decoded as 'C25508', 'Final'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: "Amendment assembler source data {'identifier': 'I8R-JE-IGBJ(a)', 'scope':\
    \ {'global': True, 'countries': [], 'regions': [], 'sites': [], 'unknown': []},\
    \ 'enrollment': {'value': 0, 'unit': ''}, 'reasons': {'primary': 'Primary: Other',\
    \ 'secondary': 'Secondary: Other'}, 'summary': 'Protocol I8R-JE-IGBJ A Phase 3\
    \ Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment\
    \ of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus\
    \ has been amended. The new protocol is indicated by Amendment (a) and will be\
    \ used to conduct the study in place of any preceding version of the protocol.\
    \ The overall changes and rationale for the changes made to this protocol are\
    \ as follows: \\nAn exclusion criterion for patients with retinopathy or maculopathy\
    \ was added due to the potential risk of fundal hemorrhage induced by hypoglycemia.\
    \ \\nThe GlucaGen reconstitution volume was changed from 1.0 mL to 1.1 mL in accordance\
    \ with instructions in the Summary of Product Characteristics (2015). Protocol\
    \ I8R-JE-IGBJ A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular\
    \ Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients\
    \ with Diabetes Mellitus has been amended. The new protocol is indicated by Amendment\
    \ (a) and will be used to conduct the study in place of any preceding version\
    \ of the protocol. The overall changes and rationale for the changes made to this\
    \ protocol are as follows: \u2022 An exclusion criterion for patients with retinopathy\
    \ or maculopathy was added due to the potential risk of fundal hemorrhage induced\
    \ by hypoglycemia. \u2022 The GlucaGen reconstitution volume was changed from\
    \ 1.0 mL to 1.1 mL in accordance with instructions in the Summary of Product Characteristics\
    \ (2015). Protocol I8R-JE-IGBJ A Phase 3 Study of Nasal Glucagon (LY900018) Compared\
    \ to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese\
    \ Patients with Diabetes Mellitus has been amended. The new protocol is indicated\
    \ by Amendment (a) and will be used to conduct the study in place of any preceding\
    \ version of the protocol. The overall changes and rationale for the changes made\
    \ to this protocol are as follows: \u2022 An exclusion criterion for patients\
    \ with retinopathy or maculopathy was added due to the potential risk of fundal\
    \ hemorrhage induced by hypoglycemia. \u2022 The GlucaGen reconstitution volume\
    \ was changed from 1.0 mL to 1.1 mL in accordance with instructions in the Summary\
    \ of Product Characteristics (2015).', 'impact': {'safety_and_rights': {'safety':\
    \ {'substantial': True, 'reason': 'Specifically implemented to decrease safety\
    \ risks.'}, 'rights': {'substantial': True, 'reason': 'Specifically implemented\
    \ to decrease safety risks.'}}, 'reliability_and_robustness': {'reliability':\
    \ {'substantial': False, 'reason': ''}, 'robustness': {'substantial': False, 'reason':\
    \ ''}}}, 'changes': [{'description': 'An exclusion criterion for patients with\
    \ retinopathy or maculopathy was added due to the potential risk of fundal hemorrhage\
    \ induced by hypoglycemia.', 'rationale': 'Mitigate risk of fundal hemorrhage\
    \ induced by hypoglycemia.', 'section': 'Section 6'}, {'description': 'The GlucaGen\
    \ reconstitution volume was changed from 1.0 mL to 1.1 mL in accordance with instructions\
    \ in the Summary of Product Characteristics (2015).', 'rationale': 'Ensure alignment\
    \ with Summary of Product Characteristics (2015)', 'section': 'Section 9'}]}"
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: Amendment reason 'Other' decoded as 'C17649', 'Other'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: Amendment reason 'Other' decoded as 'C17649', 'Other'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.assembler.amendments_assembler.AmenementsAssembler
    method_name: _create_scope
  message: Created scope of type Global
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: 'Scopes created in assembler, geo: [GeographicScope(id=''GeographicScope_2'',
    extensionAttributes=[], type=Code(id=''Code_55'', extensionAttributes=[], code=''C68846'',
    codeSystem=''http://www.cdisc.org'', codeSystemVersion=''2025-09-26'', decode=''Global'',
    instanceType=''Code''), code=None, instanceType=''GeographicScope'')], sites:
    None'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.assembler.amendments_assembler.AmenementsAssembler
    method_name: _create_amendment_impact
  message: 'Creating amendment impacts using {''safety_and_rights'': {''safety'':
    {''substantial'': True, ''reason'': ''Specifically implemented to decrease safety
    risks.''}, ''rights'': {''substantial'': True, ''reason'': ''Specifically implemented
    to decrease safety risks.''}}, ''reliability_and_robustness'': {''reliability'':
    {''substantial'': False, ''reason'': ''''}, ''robustness'': {''substantial'':
    False, ''reason'': ''''}}}'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.assembler.amendments_assembler.AmenementsAssembler
    method_name: _extract_section_numer_and_title
  message: 'Extracted section ref from ''Section 6'' -> {''sectionNumber'': ''6'',
    ''sectionTitle'': '''', ''appliesToId'': ''StudyDefinitionDocument_1'', ''id'':
    ''DocumentContentReference_1'', ''instanceType'': ''DocumentContentReference''}'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.assembler.amendments_assembler.AmenementsAssembler
    method_name: _extract_section_numer_and_title
  message: 'Extracted section ref from ''Section 9'' -> {''sectionNumber'': ''9'',
    ''sectionTitle'': '''', ''appliesToId'': ''StudyDefinitionDocument_1'', ''id'':
    ''DocumentContentReference_2'', ''instanceType'': ''DocumentContentReference''}'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.encoder.encoder.Encoder
    method_name: phase
  message: Trial phase '3' decoded as 'C15602', 'Phase 3', using M11 decode
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.assembler.study_assembler.StudyAssembler
    method_name: _get_study_name_label
  message: Study name set to 'I8RJEIGBJ'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
